NCT06392477 - A Study of DR-0201 in Subjects With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 8, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

December 31, 2026

Conditions

B-cell Non Hodgkin Lymphoma

Interventions

DRUG

DR-0201

DR-0201 is a bispecific antibody

Trial Locations (20)

100

RECRUITING

Dren Investigational Site, Taipei

505

RECRUITING

Dren Investigational Site, Chang-hua

833

RECRUITING

Dren Investigational Site, Kaohsiung City

2050

RECRUITING

Dren Investigational Site, Camperdown

3121

RECRUITING

Dren Investigational Site, Richmond

4814

RECRUITING

Dren Investigational Site, Douglas

5000

RECRUITING

Dren Investigational Site, Adelaide

6009

RECRUITING

Dren Investigational Site, Nedlands

10408

RECRUITING

Dren Investigational Site, Goyang-si

11000

RECRUITING

Dren Investigational Site, Belgrade

18108

RECRUITING

Dren Investigational Site, Niš

21204

RECRUITING

Dren Investigational Site, Kamenica

34000

RECRUITING

Dren Investigational Site, Kragujevac

48108

RECRUITING

Dren Investigational Site, Busan

49201

RECRUITING

Dren Investigational Site, Busan

119074

RECRUITING

Dren Investigational Site 3, Kent Ridge

308433

RECRUITING

Dren Investigational Site 1, Novena

999077

RECRUITING

Dren Investigational Site, Hong Kong

03080

RECRUITING

Dren Investigational Site, Seoul

06351

RECRUITING

Dren Investigational Site, Seoul